Oral treprostinil, approved for the treatment of pulmonary arterial hypertension, remains an attractive option in combination with other medications to delay disease progression and improve exercise capacity. However, patients are often challenged with the ability to overcome adverse effects as outpatients and reach effective doses in a timely manner. We describe a case of a 47-year-old female on oral treprostinil who presented to the clinic with worsening symptoms of disease, necessitating higher dosing. This patient was previously uptitrated outpatient with oral treprostinil, which had allowed her to remain stable for years. Once uptitrated with additional intravenous therapy, the oral treprostinil dose was gradually further increased to the new goal dosage, resulting in improvements in symptoms and right ventricular function. This case highlights the versatility of dose optimization of oral treprostinil with rapid bridging through intravenous therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10948086 | PMC |
| http://dx.doi.org/10.7759/cureus.54184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.
Chest
November 2024
University of Michigan, Ann Arbor, MI, USA. Electronic address:
Background: An increasing number of patients with pulmonary arterial hypertension (PAH) have cardiovascular comorbidities. However, the effects of comorbidities on responses to PAH treatment are not well understood.
Research Question: Do cardiovascular comorbidities in patients with PAH influence the efficacy and tolerability of inhaled or oral treprostinil?
Study Design And Methods: All patients from phase 3 studies TRIUMPH (N = 235) and FREEDOM-EV (N = 690) were included in this post hoc analysis and were classified as having 0, ≥1, or ≥2 cardiovascular comorbidities of interest based on patients' medical histories.
Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis.
Postepy Kardiol Interwencyjnej
September 2024
Department of Nephrology, The Fifth People's Hospital of Ganzhou, Ganzhou, China.
Introduction: Pulmonary arterial hypertension (PAH) is a progressive condition characterized by elevated blood pressure in the pulmonary arteries, leading to significant morbidity and mortality. Treprostinil, a synthetic analogue of prostacyclin, has emerged as a potential treatment option.
Aim: The efficacy and safety of oral treprostinil in PAH patients remain subjects of ongoing research.
The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure.
Eur J Med Res
October 2024
Department of Pediatric Intensive Care Unit, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People's Republic of China.
Article Synopsis
- The study investigated the effects of different administration regimens of intravenous treprostinil, a medication used in high-risk pediatric patients who underwent total cavo-pulmonary connection (TCPC) surgery, to improve postoperative recovery.
- It included a retrospective analysis of 51 pediatric patients divided into two groups based on the timing and dosing of treprostinil: Group 1 (earlier administration) and Group 2 (within one day post-surgery).
- Results showed comparable reductions in mean pulmonary arterial pressure (mPAP) after treatment in both groups, indicating that the timing of treprostinil administration may not significantly impact early postoperative outcomes.
ORENITRAM's decadal journey: unveiling safety profiles and adverse event through a real-world pharmacovigilance study of FAERS events.
Expert Opin Drug Saf
September 2024
Research Center for High Altitude Medicine, Qinghai University, Xining, Qinghai, China.
Background: ORENITRAM, an oral treprostinil formulation, was approved in 2013 for pulmonary arterial hypertension (PAH) treatment, necessitating ongoing safety monitoring.
Research Design And Methods: This retrospective analysis used FDA Adverse Event Reporting System data from Q4 2013 to Q4 2023, employing disproportionality analysis and the reporting odds ratio (ROR) to identify adverse events (AEs) linked with ORENITRAM.
Results: Out of 15,660,695 reports, ORENITRAM was the primary suspect in 10,125 cases.
Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus.
Respir Med
September 2024
Houston Methodist Hospital, Houston, TX, USA. Electronic address:
Background: Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH) by delaying disease progression and improving exercise capacity. Higher doses of oral treprostinil correlate with increased treatment benefit. Titrations may be challenging due to common side effects of prostacyclin-class therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!